ストックスクリーナーアプリを入手
143.31
0.19%
-0.28
アフターアワーズ：
143.31
Revvity Inc (RVTY) 最新ニュース
(RVTY) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revvity Inc Share PriceRVTY, RNS News, Articles, Quotes, & Charts (NYSE:RVTY) - Proactive financial news
Revvity, Inc. rStock (RRVTY) Price Prediction for 2026 to 2031 - bybit.com
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery - Yahoo Finance
Revvity Inc. stock gains momentum as UBS adjusts price target and Q2 2026 revenue edges higher - ad-hoc-news.de
Top Revvity (RVTY) Competitors 2026 - MarketBeat
Revvity stock heads into the open after a 2.35% slide - ad-hoc-news.de
Revvity Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Revvity (RVTY) Receives a New Rating from UBS - The Globe and Mail
Revvity stock heads into the open after a 2.5% Nasdaq drop - ad-hoc-news.de
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity, Inc. entered into a definitive agreement to acquire Human Cell Design SAS. - marketscreener.com
Revvity to acquire Human Cell Design for metabolic research tools By Investing.com - Investing.com Australia
RVTY Assumes Rating by UBS -- Price Target Raised to $140 - GuruFocus
Revvity at Wells Fargo 21st annual healthcare conference: growth and margin focus - Investing.com India
Revvity Acquiring French Firm Human Cell Design - GenomeWeb
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition - Benzinga
UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120 - marketscreener.com
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery - BioSpace
Revvity, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow - GuruFocus
Revvity to Acquire Human Cell Design - marketscreener.com
Revvity to acquire Human Cell Design - TradingView
Revvity to acquire Human Cell Design for metabolic research tools - investing.com
A planned Revvity deal would add human pancreatic cells for diabetes research - Stock Titan
Revvity Inc. stock slips despite solid Q2 2026 growth and cautious analyst outlook - ad-hoc-news.de
Revvity stock heads into the open after a 2.1 percent drop - ad-hoc-news.de
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
T. Rowe Price controls over 10M Revvity (NYSE: RVTY) shares, with one fund holding about half the stake - Stock Titan
Revvity Inc. stock holds above 130 dollars as analysts stick with Hold ratings - ad-hoc-news.de
Revvity, Inc. (RVTY) Stock Analysis: Navigating Potential in the Diagnostics Sector Amid Mixed Ratings - DirectorsTalk Interviews
KeyBanc Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? - Yahoo Finance
KeyBanc Adjusts Price Target on Revvity to $165 From $125, Maintains Overweight Rating - marketscreener.com
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Revvity Inc. stock holds near 52-week high as valuation debate intensifies - AD HOC NEWS
Baird Adjusts Price Target on Revvity to $144 From $131, Keeps Outperform Rating - marketscreener.com
Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings - finance.yahoo.com
Revvity Inc (RVTY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade - Yahoo Finance
What Makes Revvity (RVTY) a New Buy Stock - finance.yahoo.com
Revvity Faces Growth Challenges Amid Rising Competition, RBC Says - marketscreener.com
RBC Initiates Revvity at Sector Perform With $135 Price Target - marketscreener.com
RBC Capital initiates Revvity stock with Sector Perform rating By Investing.com - Investing.com Australia
RBC Capital initiates Revvity stock with Sector Perform rating - investing.com
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity, Inc. (RVTY) Stock Analysis: Navigating a 6% Potential Downside with Strategic Insights - DirectorsTalk Interviews
Revvity (RVTY) Eases to $128.8: Key Support at $122.36 Holds in FocusImbalance Zone - vinanet.vn
Revvity Inc stock hits 52-week high at 130.07 USD By Investing.com - Investing.com Nigeria
Revvity Inc stock hits 52-week high at 130.07 USD - Investing.com
RVTY Stock Price and Chart — NYSE:RVTY - TradingView
Revvity (NYSE: RVTY) director donates 285 shares in stock gift - Stock Titan
Can Revvity (RVTY) Turn Decentralized Prenatal Screening Into a Durable Diagnostics Advantage? - simplywall.st
Revvity stock trades around $123 as investors weigh latest earnings and analyst targets - Ad-hoc-news.de
Why Revvity (RVTY) Stock Is Up Today - Quiver Quantitative
Revvity stock hits new 52-week high as gains extend - Ad-hoc-news.de
Revvity stock hits 52-week high at 122.26 USD - Investing.com
Revvity stock hits 52-week high at 122.26 USD By Investing.com - Investing.com India
Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors - GuruFocus
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Revvity stock edges lower as SuperFlex launch and Q2 earnings shape valuation debate - Ad-hoc-news.de
Revvity Inc (RVTY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
4.13%
4.22%
大文字化:
|
ボリューム (24 時間):